| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
138,140,000 |
| Market
Cap: |
142.28(M) |
| Last
Volume: |
3,241,097 |
Avg
Vol: |
3,286,692 |
| 52
Week Range: |
$0.92 - $1.31 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 807 |
| Guru Rank Value : 1 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Spectrum Pharmaceuticals is a biopharmaceutical company. Co. is engaged in acquiring, developing, and commercializing targeted oncology therapies. Co. has two drugs in late-stage development: Eflapegrastim, which is a long-acting granulocyte colony-stimulating factor for the treatment of chemotherapy-induced neutropenia; as well as Poziotinib, which is an irreversible tyrosine kinase inhibitor under investigation for non-small cell lung cancer tumors with various mutations.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
50,000 |
| Total Buy Value |
$0 |
$0 |
$0 |
$22,500 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
0 |
0 |
32,387 |
490,738 |
| Total Sell Value |
$0 |
$0 |
$35,496 |
$343,474 |
| Total People Sold |
0 |
0 |
1 |
7 |
| Total Sell Transactions |
0 |
0 |
1 |
19 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vacirca Jeff L |
Director |
– • – |
2022-10-27 |
4 |
A |
$0.43 |
$21,500 |
D/D |
50,000 |
220,244 |
|
- |
|
| Fischer Seth H.z. |
Director |
– • – |
2022-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
54,066 |
|
- |
|
| Vacirca Jeff L |
Director |
– • – |
2022-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
195,244 |
|
- |
|
| Lim Juhyun |
Director |
– • – |
2022-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
29,759 |
|
- |
|
| Ashton William |
Director |
– • – |
2022-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
67,660 |
|
- |
|
| Bradrick Brittany |
Director |
– • – |
2022-08-31 |
4 |
A |
$0.00 |
$0 |
D/D |
27,380 |
27,380 |
|
- |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2022-06-23 |
4 |
AS |
$0.84 |
$5,594 |
D/D |
(6,667) |
644,790 |
|
-52% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2022-06-22 |
4 |
AS |
$0.81 |
$4,913 |
D/D |
(6,096) |
651,457 |
|
-43% |
|
| Riga Thomas J |
CEO & President |
• • – |
2022-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
405,040 |
1,213,340 |
|
- |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2022-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
405,040 |
657,553 |
|
- |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2022-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
246,085 |
491,025 |
|
- |
|
| Brennan Nora |
EVP & CFO |
• – – |
2022-06-21 |
4 |
AS |
$0.79 |
$2,802 |
D/D |
(3,569) |
360,215 |
|
-45% |
|
| Brennan Nora |
EVP & CFO |
• – – |
2022-06-21 |
4 |
A |
$0.00 |
$0 |
D/D |
334,507 |
363,784 |
|
- |
|
| Fischer Seth H.z. |
Director |
– • – |
2022-06-21 |
4 |
AS |
$0.79 |
$4,483 |
D/D |
(5,711) |
29,066 |
|
-45% |
|
| Vyas Dolatrai |
Former Director |
– – – |
2022-06-21 |
4 |
AS |
$0.79 |
$3,362 |
D/D |
(4,283) |
82,063 |
|
-45% |
|
| Ashton William |
Director |
– • – |
2022-06-21 |
4 |
AS |
$0.79 |
$3,362 |
D/D |
(4,283) |
42,660 |
|
-45% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2022-04-05 |
4 |
AS |
$1.41 |
$1,927 |
D/D |
(1,367) |
252,513 |
|
20% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2022-04-04 |
4 |
AS |
$1.35 |
$1,627 |
D/D |
(1,205) |
253,880 |
|
-3% |
|
| Lim Juhyun |
Director |
– • – |
2022-03-25 |
4 |
A |
$0.00 |
$0 |
D/D |
4,759 |
4,759 |
|
- |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2022-03-16 |
4 |
AS |
$0.71 |
$11,521 |
D/D |
(16,318) |
244,940 |
|
6% |
|
| Riga Thomas J |
CEO & President |
• • – |
2022-03-16 |
4 |
AS |
$0.71 |
$13,293 |
D/D |
(18,829) |
568,800 |
|
6% |
|
| Lebel Francois |
Chief Medical Officer |
• – – |
2022-03-16 |
4 |
AS |
$0.71 |
$17,724 |
D/D |
(25,105) |
255,085 |
|
6% |
|
| Gustafson Kurt A |
EVP & Chief Financial Officer |
• – – |
2022-03-16 |
4 |
AS |
$0.71 |
$11,521 |
D/D |
(16,318) |
317,259 |
|
6% |
|
| Mcgahan Keith M |
Chief Legal Officer |
• – – |
2022-03-15 |
4 |
AS |
$0.71 |
$10,334 |
D/D |
(14,658) |
261,258 |
|
12% |
|
| Riga Thomas J |
CEO & President |
• • – |
2022-03-15 |
4 |
AS |
$0.71 |
$14,351 |
D/D |
(20,356) |
587,629 |
|
12% |
|
658 Records found
|
|
Page 2 of 27 |
|
|
